#United States #New York #Caribou Biosciences #CRBU #GLaw Firm

Legal Notice to Shareholders of Caribou Biosciences, Inc. (CRBU)

The Gross Law Firm has recently notified shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU) regarding a class action lawsuit that could have significant implications for investors. This notice emphasizes the importance of prompt action by shareholders who purchased shares within the specified timeframe. The firm encourages eligible shareholders to reach out for potential lead plaintiff appointment.

Overview of the Class Action Lawsuit

The lawsuit arises from allegations that Caribou Biosciences made materially false and misleading statements about its operations and financial statuses. Particularly, it claims that, between July 14, 2023, and July 16, 2024, the company overstated the safety and efficacy of its leading product, CB-010. This product is designed for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL).

Among the key allegations are claims that:
1. The efficacy and safety of CB-010 were overstated compared to existing treatments that are approved for patient use.
2. Caribou faced severe liquidity issues that could jeopardize its ability to sustain business operations, which included preclinical research on its allogeneic CAR-NK platform.
3. Misleading statements made by the defendants throughout this period clouded Caribou's clinical results and overall commercial potential, impacting the company's stock performance adversely.

Key Dates and Actions for Shareholders

Shareholders are urged to not delay in registering for participation in this class action. The deadline to register as a lead plaintiff is February 24, 2025. Should shareholders wish to partake in potential recovery under this lawsuit, they can find the registration forms via the Gross Law Firm’s dedicated webpage.

Additionally, once registered, shareholders will be enrolled in a portfolio monitoring software that will keep them updated throughout the case lifecycle. This ensures that they are informed of all relevant developments as they unfold, making it easier to navigate the claims process.

Why Choose Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized entity in managing class action cases, committed to safeguarding the interests of investors affected by deceptive practices. The firm seeks accountability from companies to foster ethical business operations and is focused on helping investors recover losses incurred due to potentially misleading corporate statements.

Through thorough investigation and advocacy, the firm aspires to rectify deceits that undermine investor confidence and uphold the integrity of stock markets. Furthermore, no fees or costs are imposed upon the shareholder to participate in this class action, underscoring the firm’s mission of accessible justice for all.

Conclusion

Investors who have faced financial losses during this turbulent period for Caribou Biosciences should act swiftly to assert their rights. The upcoming deadline emphasizes the urgency of the situation, and those eligible must ensure that they’re registered to maximize their chance of recovery. For further inquiries or to seek assistance, shareholders can contact the Gross Law Firm directly via their provided contact information.

• ---

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: 646-453-8903